# Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

- URL: https://theranews.net/blog/2026-02-18-compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-f3812e/
- Published: 2026-02-18
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: rutlandherald
- Original report: https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

---
![Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression](/uploads/news-images/compass-pathways-successfully-achieves-primary-end-20260218110051.jpg)

---
*Originally reported by rutlandherald. [Read more](https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html)*

---

*Source: [https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html](https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html)*